Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. (Q33288696)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author

Vaishali Sanchorawala

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Karen Quillen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

John L Berk

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Gheorghe Doros

1 reference

ORCID Public Data File 2021

author name string

Wright DG

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Finn KT

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Dember LM

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Doros G

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Fisher C

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Skinner M

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Seldin DC

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

language of work or name

English

0 references

publication date

25 June 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

1 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

557-562

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705746

1 January 2020

exact match

0 references

cites work

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

7 January 2021

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

7 January 2021

High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

7 January 2021

Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

7 January 2021

Single versus double autologous stem-cell transplantation for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

7 January 2021

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

7 January 2021

Spontaneous rupture of the spleen in AL amyloidosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

7 January 2021

Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

7 January 2021

Outcome of autologous stem cell transplantation for AL amyloidosis in the UK

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

7 January 2021

Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

7 January 2021

High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

7 January 2021

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

7 January 2021

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

7 January 2021

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

7 January 2021

Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

7 January 2021

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

7 January 2021

Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705746

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705746

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17589534%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

1 January 2020

0 references

1 reference